Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.61 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.61 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9437046 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL19917793 | 1.00 | LPAR3 (0.61) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL12341207 | 0.91 | LPAR3 (0.54) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL9437039 | 0.88 | LPAR3 (0.45) | LPAR3LPAR2LPAR1SMPD1 | |
| SCHEMBL13322581 | 0.87 | LPAR3 (0.47) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| Trolamine SCHEMBL10438012 | 0.87 | LPAR3 (0.47) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL10438013 | 0.87 | LPAR3 (0.47) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL7735902 | 0.85 | LPAR3 (0.64) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL7733418 | 0.85 | LPAR3 (0.64) | LPAR3LPAR2LPAR1SMPD1LPAR5 | |
| SCHEMBL19509501 | 0.82 | LPAR3 (0.46) | LPAR3LPAR2LPAR1SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317521-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2021-10-14 | — | — | US | disclosed |
| US-11008613-B2 | Tagged nucleotides useful for nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200216894-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10669580-B2 | Tagged nucleotides useful for nanopore detection | Roche Sequencing Solutions, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180057870-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | Roche Sequencing Solutions, Inc. | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669580-B2 | Tagged nucleotides useful for nanopore detection | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-20180057870-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-20200216894-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-20210317521-A1 | TAGGED NUCLEOTIDES USEFUL FOR NANOPORE DETECTION | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
| US-11008613-B2 | Tagged nucleotides useful for nanopore detection | PHAX, POLRMT, POLN | LPAR3 3474/4885LPAR2 3499/4885LPAR1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.